ENTERA BIO LTD. Other Labor-related Expenses
ENTERA BIO LTD. (ENTX) reported Other Labor-related Expenses of $4.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherLaborRelatedExpenses · last filed 2026-08-07
- ENTERA BIO LTD. other labor-related expenses for the quarter ending 2026-06-30 was $4.11M, a 261.88% increase year-over-year.
- ENTERA BIO LTD. other labor-related expenses for the quarter ending 2026-03-31 was $1.25M, a 15.61% decline year-over-year.
- ENTERA BIO LTD. other labor-related expenses for the quarter ending 2025-12-31 was $1.30M, a 4.76% increase year-over-year.
- ENTERA BIO LTD. other labor-related expenses for the quarter ending 2025-09-30 was $1.56M, a 1.83% decline year-over-year.
- ENTERA BIO LTD. other labor-related expenses for fiscal 2025 was $5.48M, a 4.86% increase from fiscal 2024.
- ENTERA BIO LTD. other labor-related expenses for fiscal 2024 was $5.22M.
| Period end | Other Labor-related Expenses 3 month | Other Labor-related Expenses 6 month | Other Labor-related Expenses 9 month | Other Labor-related Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.11M 10-Q · filed 2026-08-07 | $5.37M 10-Q · filed 2026-08-07 | $6.66M derived: sum of 3 quarters · filed 2026-08-07 | $8.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.25M 10-Q · filed 2026-05-08 | $2.55M derived: sum of 2 quarters · filed 2026-05-08 | $4.11M derived: sum of 3 quarters · filed 2026-05-08 | $5.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.85M derived: sum of 2 quarters · filed 2026-03-27 | $3.99M derived: sum of 3 quarters · filed 2026-08-07 | $5.48M 10-K · filed 2026-03-27 |
| 2025-09-30 | $1.56M 10-Q · filed 2025-11-14 | $2.69M derived: sum of 2 quarters · filed 2026-08-07 | $4.18M 10-Q · filed 2025-11-14 | $5.42M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.14M 10-Q · filed 2026-08-07 | $2.62M 10-Q · filed 2026-08-07 | $3.86M derived: sum of 3 quarters · filed 2026-08-07 | $5.45M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.49M 10-Q · filed 2026-05-08 | $2.73M derived: sum of 2 quarters · filed 2026-05-08 | $4.31M derived: sum of 3 quarters · filed 2026-05-08 | $5.43M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.83M derived: sum of 2 quarters · filed 2026-03-27 | $3.94M derived: sum of 3 quarters · filed 2026-03-27 | $5.22M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.59M 10-Q · filed 2025-11-14 | $2.71M derived: sum of 2 quarters · filed 2025-11-14 | $3.98M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $1.12M 10-Q · filed 2025-08-08 | $2.40M 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |